Research programme: antibody therapeutics - TaiMed Biologics/Rockefeller University

Drug Profile

Research programme: antibody therapeutics - TaiMed Biologics/Rockefeller University

Alternative Names: LM 52; TMB 360; TMB-365; TMB-Bispecific

Latest Information Update: 11 Jul 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Aaron Diamond AIDS Research Center
  • Class Bispecific antibodies; Monoclonal antibodies
  • Mechanism of Action CD4 antigen inhibitors; HIV envelope protein gp120 inhibitors; Virus internalisation inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical HIV infections

Most Recent Events

  • 20 May 2016 TaiMed Biologics in-licenses TMB 365-relevant technology platform from the Aaron Diamond AIDS Research Center (before May 2016; TaiMed Biologics website, May 2016)
  • 20 May 2016 Preclinical trials in HIV infections in Taiwan (Parenteral) (before May 2016; TaiMed Biologics pipeline, May 2016)
  • 20 May 2016 TaiMed Biologics plans a phase I trial for HIV infections in Taiwan (TaiMed Biologics pipeline, May 2016)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top